ClinicalTrials.gov
public full text
Public Domain
A Phase 1 Dose Escalation Study of IPI-493
IPI-493 is a potent inhibitor of heat shock protein 90 (Hsp90) and is orally bioavailable via a novel formulation.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of Heat Shock Proteins as Prognostic Factor of Acute Renal Failure in Children (HSP-Study)#803918
- Treatment and Prevention of Heat-Related Illness#383821
- Mild Hypothermia and Supplemental Magnesium Sulfate Infusion in Severe Traumatic Brain Injury (TBI) Subjects#1137574
- Heat treatment combined with hybrid exercises retraining mitigates cellular markers of protein turnover after hindlimb suspension in male mice: A pilot study#322535
- Meal Delivery and Exercise#861289
Record · ID 1047778
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive